The November 10 hearing outcome is binary: if the Panel grants an exception, the stock may stabilize; if not, delisting risk materializes. Monitor for any equity financing or business development announcements ahead of the hearing that could strengthen the balance sheet.
Price Chart
Executive Summary
NeuroSense announced its Nasdaq hearing is scheduled for November 10, 2026, following a delisting determination for failing the $35 million minimum market value of listed securities requirement. The company has regained bid-price compliance and will present a plan to meet the market value or alternative stockholders' equity standard, while targeting a Health Canada New Drug Submission for PrimeC in ALS by December 2026 and a non-dilutive grant decision in Q1 2027.
Key Facts
- Nasdaq hearing scheduled for November 10, 2026, after October 1 Staff Delisting Determination
- Only remaining deficiency is the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2)
- Minimum bid price compliance has been regained
- Health Canada New Drug Submission for PrimeC in ALS targeted for December 2026
- Decision on non-dilutive grant funding for Phase 3 PARAGON trial expected in Q1 2027
- Shares continue trading on Nasdaq pending the Panel's decision
Financial Impact
Delisting risk remains unresolved; the company must address a $35 million market value deficiency or meet a $2.5 million stockholders' equity alternative. No financial figures were provided in the filing.
Risk Factors
- Nasdaq Panel may not grant an exception, leading to delisting
- Health Canada submission or grant funding may be delayed or denied
- Company may need to raise capital on dilutive terms to meet listing requirements
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108759 |
| Document: ea0308436-6k_neurosense.htm | 0001213900-26-108759 |
| Document: 0001213900-26-108759-index-headers.html | 0001213900-26-108759 |
| Document: 0001213900-26-108759-index.html | 0001213900-26-108759 |
| Document: 0001213900-26-108759.txt | 0001213900-26-108759 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $2.67 $2.39 | ▼ −10.32% | ▼ −10.65% | $2.46 (−7.69%) |
Oct 13, 2026 13d ago | 6-K | $3.49 $3.06 | ▼ −12.32% | ▼ −11.24% | $2.46 (−29.51%) |
Sep 25, 2026 4w ago | 6-K | $5.10 $4.78 | ▲ +6.27% | ▲ +6.09% | $2.46 (+51.76%) |
Aug 6, 2026 11w ago | 6-K | $0.5030 $0.4999 | ▼ −0.62% | ▼ −1.23% | $2.46 (+389.07%) |
Jul 22, 2026 13w ago | 6-K | $0.6500 $0.6550 | ▲ +0.77% | ▲ +2.00% | $2.46 (+278.46%) |
Jun 29, 2026 17w ago | 6-K | $0.7099 $0.7200 | ▲ +1.42% | ▲ +0.64% | $2.46 (+246.53%) |
Jun 17, 2026 18w ago | Insider Cluster | $16.10 $15.78 | ▼ −1.99% | ▼ −1.67% | $2.46 (−84.72%) |
Jun 11, 2026 19w ago | 6-K | $0.7390 $0.7352 | ▼ −0.51% | ▼ −1.05% | $2.46 (+232.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers